{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:43:20Z","timestamp":1785415400646,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cllc.2024.05.007","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T06:33:38Z","timestamp":1716618818000},"page":"e337-e347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Primary Stereotactic Body Radiotherapy for Spinal Bone Metastases From Lung Adenocarcinoma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-4285","authenticated-orcid":false,"given":"Kuan-Nien","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke S.","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit R.","family":"Persad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara C.","family":"Emrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Ustrzynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Tayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Usoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erqi","family":"Pollom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Soltys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiue-Wei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cllc.2024.05.007_bib0001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc.2016.56","article-title":"Biomarker development in the precision medicine era: lung cancer as a case study","volume":"16","author":"Vargas","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"7689","key":"10.1016\/j.cllc.2024.05.007_bib0002","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cllc.2024.05.007_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JTO.0000000000000051","article-title":"Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13","volume":"9","author":"Katakami","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2024.05.007_bib0004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2024.05.007_bib0005","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1038\/srep18670","article-title":"Natural history of non-small-cell lung cancer with bone metastases","volume":"5","author":"Santini","year":"2015","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.cllc.2024.05.007_bib0006","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.21037\/jtd-21-1502","article-title":"Bone metastases in non-small cell lung cancer: a narrative review","volume":"14","author":"Knapp","year":"2022","journal-title":"J Thorac Dis"},{"issue":"26","key":"10.1016\/j.cllc.2024.05.007_bib0007","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1200\/JCO.2014.55.4675","article-title":"Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice","volume":"32","author":"Timmerman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2024.05.007_bib0008","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1148\/rg.2021210052","article-title":"Fundamentals of radiation oncology for treatment of vertebral metastases","volume":"41","author":"Gottumukkala","year":"2021","journal-title":"Radiographics"},{"issue":"2","key":"10.1016\/j.cllc.2024.05.007_bib0009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/PAI.0000000000000531","article-title":"Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non-small cell lung carcinoma","volume":"26","author":"Parra","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.cllc.2024.05.007_bib0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.lungcan.2017.08.005","article-title":"PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review","volume":"112","author":"Brody","year":"2017","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.cllc.2024.05.007_bib0011","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/1759-7714.12247","article-title":"Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics","volume":"6","author":"Zhang","year":"2015","journal-title":"Thorac Cancer"},{"issue":"8","key":"10.1016\/j.cllc.2024.05.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136023","article-title":"PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups","volume":"10","author":"Schmidt","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cllc.2024.05.007_bib0013","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/BRS.0b013e3181913f19","article-title":"Outcome of treatment for spinal metastases using scoring system for preoperative evaluation of prognosis","volume":"34","author":"Tokuhashi","year":"2009","journal-title":"Spine"},{"issue":"22","key":"10.1016\/j.cllc.2024.05.007_bib0014","doi-asserted-by":"crossref","first-page":"E1221","DOI":"10.1097\/BRS.0b013e3181e16ae2","article-title":"A novel classification system for spinal instability in neoplastic disease: An evidence-based approach and expert consensus from the Spine Oncology Study Group","volume":"35","author":"Fisher","year":"2010","journal-title":"Spine (Phila Pa 1976)"},{"issue":"2","key":"10.1016\/j.cllc.2024.05.007_bib0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3174\/ajnr.A4528","article-title":"Osseous pseudoprogression in vertebral bodies treated with stereotactic radiosurgery: a secondary analysis of prospective phase I\/II clinical trials","volume":"37","author":"Amini","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"10.1016\/j.cllc.2024.05.007_bib0016","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.ijrobp.2012.03.009","article-title":"International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery","volume":"83","author":"Cox","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2024.05.007_bib0017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2019.11.026","article-title":"International consensus recommendations for target volume delineation specific to sacral metastases and spinal stereotactic body radiation therapy (SBRT)","volume":"145","author":"Dunne","year":"2020","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2024.05.007_bib0018","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2024.05.007_bib0019","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lungcan.2018.11.021","article-title":"High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment na\u00efve advanced EGFR-mutant lung adenocarcinoma patients","volume":"127","author":"Hsu","year":"2019","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2024.05.007_bib0020","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mdu370","article-title":"Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic non-small-cell lung cancer patients","volume":"25","author":"Collen","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2024.05.007_bib0021","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2018.06.400","article-title":"Long-term outcomes of a phase 2 trial of chemotherapy with consolidative radiation therapy for oligometastatic non-small cell lung cancer","volume":"102","author":"Petty","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.cllc.2024.05.007_bib0022","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.21037\/tlcr-21-794","article-title":"Racial disparities in histological subtype, stage, tumor grade and cancer-specific survival in lung cancer","volume":"11","author":"Zeng","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2024.05.007_bib0023","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/j.wneu.2022.10.061","article-title":"Which scoring system is the most accurate for assessing survival prognosis in patients undergoing surgery for spinal metastases from lung cancer? A single-center experience","volume":"168","author":"Tarabay","year":"2022","journal-title":"World Neurosurg"},{"issue":"4","key":"10.1016\/j.cllc.2024.05.007_bib0024","doi-asserted-by":"crossref","first-page":"367","DOI":"10.21037\/tlcr.2019.08.16","article-title":"Incidence, prognostic factors, and a nomogram of lung cancer with bone metastasis at initial diagnosis: a population-based study","volume":"8","author":"Zheng","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2024.05.007_bib0025","article-title":"Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials","volume":"13","author":"Lu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2024.05.007_bib0026","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","article-title":"Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody","volume":"76","author":"von Moos","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.cllc.2024.05.007_bib0027","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41571-018-0095-y","article-title":"Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy","volume":"15","author":"Ahern","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2024.05.007_bib0028","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.3390\/cells10081978","article-title":"The roadmap of RANKL\/RANK pathway in cancer","volume":"10","author":"Casimiro","year":"2021","journal-title":"Cells"},{"issue":"23","key":"10.1016\/j.cllc.2024.05.007_bib0029","first-page":"5727","article-title":"Bone metastasis of breast cancer: molecular mechanisms and therapeutic strategies","volume":"14","author":"Pang","year":"2022","journal-title":"Cancers(Basel)"},{"issue":"6937","key":"10.1016\/j.cllc.2024.05.007_bib0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"issue":"32","key":"10.1016\/j.cllc.2024.05.007_bib0031","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.2174\/092986712803833209","article-title":"Bone metastases and non-small cell lung cancer: From bisphosphonates to targeted therapy","volume":"19","author":"Rossi","year":"2012","journal-title":"Curr Med Chem"},{"issue":"9","key":"10.1016\/j.cllc.2024.05.007_bib0032","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/2326-6066.CIR-14-0069","article-title":"Combining radiation and immunotherapy: a new systemic therapy for solid tumors?","volume":"2","author":"Tang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.cllc.2024.05.007_bib0033","first-page":"83","article-title":"PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer","volume":"22","author":"Narits","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"4","key":"10.1016\/j.cllc.2024.05.007_bib0034","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2024.05.007_bib0035","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2021.12.162","article-title":"Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation","volume":"112","author":"Du","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.cllc.2024.05.007_bib0036","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.3390\/cancers14122829","article-title":"Radioresistance of non-small cell lung cancers and therapeutic perspectives","volume":"14","author":"C\u00e9saire","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cllc.2024.05.007_bib0037","doi-asserted-by":"crossref","first-page":"140","DOI":"10.4149\/neo_2018_170206N77","article-title":"PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy","volume":"65","author":"Vrankar","year":"2018","journal-title":"Neoplasma"},{"issue":"1","key":"10.1016\/j.cllc.2024.05.007_bib0038","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.tranon.2016.01.003","article-title":"PD-L1 Expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy","volume":"9","author":"Sorensen","year":"2016","journal-title":"Transl Oncol"},{"key":"10.1016\/j.cllc.2024.05.007_bib0039","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejca.2019.10.019","article-title":"Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors","volume":"124","author":"Yang","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.cllc.2024.05.007_bib0040","first-page":"5","article-title":"Adenocarcinoma classification: patterns and prognosis","volume":"110","author":"Kuhn","year":"2018","journal-title":"Pathologica"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730424001062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T15:48:34Z","timestamp":1729871314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730424001062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1525730424001062"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2024.05.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Stereotactic Body Radiotherapy for Spinal Bone Metastases From Lung Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2024.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}